About Cellics
Cellics is a company based in San Diego (United States) founded in 2014 by Liangfang Zhang. Cellics has raised $26 million across 4 funding rounds from investors including CARB-X. The company has 18 employees as of December 31, 2022. Cellics operates in a competitive market with competitors including Imbed Biosciences, Cour Pharma, PharmaJet, Arecor and Suono Bio, among others.
- Headquarter San Diego, United States
- Employees 18 as on 31 Dec, 2022
- Founders Liangfang Zhang
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cellics Therapeutics Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$26 M (USD)
in 4 rounds
-
Latest Funding Round
$3.94 M (USD), Grant
Oct 21, 2020
- Investors
-
Employee Count
18
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cellics
Unlock access to complete
Unlock access to complete
Funding Insights of Cellics
Cellics has successfully raised a total of $26M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $3.94 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cellics
Cellics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include CARB-X.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed.
|
Locked | Locked | Locked |
Investor details for Cellics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellics
Investment portfolio details for Cellics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellics
Detailed financials for Cellics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellics Comparisons
Peer comparison for Cellics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellics
Cellics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Imbed Biosciences, Cour Pharma, PharmaJet, Arecor and Suono Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Nanotech-based wound care products are developed and provided.
|
|
| Locked | Locked | Locked |
Biotech nanoparticles are developed for immune disease treatments.
|
|
| Locked | Locked | Locked |
Provider of needle-free injection technology
|
|
| Locked | Locked | Locked |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
|
| Locked | Locked | Locked |
Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract
|
|
| Locked | Locked | Locked |
Drugs for neurological diseases are discovered and developed.
|
Detailed competitors of Cellics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellics
Complete news archive for Cellics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellics
Cellics was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Cellics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Cellics is a funded company, having raised a total of $26M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Cellics is 18.
Cellics Therapeutics is a preclinical stage company, developing therapies for various diseases using cell membrane coating technology. The companys proprietary Nanosponge Technology is based on coating nanoparticles and nanomaterials with cellular membranes taken directly from cells. The company focuses on the development of red blood cell membrane (RBC) coated Nanosponges to develop therapies for infectious diseases, autoimmune disorders, anti-venom, and vaccines. The company claims that the nanocoated RBC membrane-coated particles would remove toxins and venoms from the bloodstream divert them from attacking normal cells. The company has product pipeline of therapies for bacterial infections, autoimmune hemolytic anemia, malaria, anti-venam and MRSA vaccine.
Cellics's top competitors include Imbed Biosciences, PharmaJet and Splice Bio.
Cellics has 1 investor. Key investors include CARB-X.